 | |
| Company type | Subsidiary |
|---|---|
| NYSE: HSP | |
| Founded | May 3, 2004 (spun off from Abbott Laboratories) |
| Headquarters | Lake Forest, Illinois, United States |
Key people | F. Michael (Mike) Ball (CEO); John C. Staley, Chairman of the Board of Directors |
| Products | Generic acute-care and oncology injectables, integrated infusion therapy, medication management systems |
| Revenue | $4.5 billion (2014) |
Number of employees | Approximately 19,000 |
| Parent | Pfizer |
| Website | www |
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees.[1] Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals,[2] manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.[3] It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
Worldwide sales in 2014 were approximately $4.5 billion.[4] Current results are now part of Pfizer's consolidated statements.
- ^ "Hospira - Investor Relations - Shareholder FAQ". Archived from the original on 28 December 2015.
- ^ "US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mn". The Economic Times. 16 December 2009. Archived from the original on April 26, 2012.
- ^ "About Hospira".
- ^ "HSP Key Statistics". Yahoo.com.